

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

Brilliant Violet 421™ anti-human IFN-?

RRID:AB_10900083

Type: Antibody

Proper Citation

BioLegend Cat# 502531, RRID:AB_10900083

Antibody Information

URL: http://antibodyregistry.org/AB_10900083

Proper Citation: BioLegend Cat# 502531, RRID:AB_10900083

Target Antigen: IFN-gamma

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 421™ anti-human IFN-?

Description: This monoclonal targets IFN-gamma

Target Organism: human

Clone ID: Clone 4S.B3

Antibody ID: AB_10900083

Vendor: BioLegend

Catalog Number: 502531

Alternative Catalog Numbers: 502532

Record Creation Time: 20250819T235713+0000

Record Last Update: 20250820T065529+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421™ anti-human IFN-γ.

No alerts have been found for Brilliant Violet 421™ anti-human IFN-γ.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Wang J, et al. (2024) LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis. EMBO molecular medicine, 16(8), 1755.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. Biochemical pharmacology, 213, 115612.

Cichocki F, et al. (2023) Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma. Science translational medicine, 15(705), eade3341.